Abstract
Encorafenib and binimetinib were registered in 2018 for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. The results of the phase III study (Columbus) are very promising. Median PFS for patients who have received this treatment was 14.9 months, and the median OS was 33.6 months. The reduction of toxicity is the reason for the unique pharmacokinetic profile of this therapy. Knowledge about the adverse evets is important in the context of optimizing and individualizing treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
